SAMH
BCLI

Shanda Asset Management Holdings’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Shanda Asset Management Holdings’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,533
Closed -$258K – 60
2020
Q2 		$258K Buy
+1,533
New +$165K 0.02% 87

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Shanda Asset Management Holdings's BCLI Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 1,533 shares — an estimated $258K sold.

Shanda Asset Management Holdings first reported a position in BCLI in Q2 2020 and held it in 1 quarter. The position peaked at $258K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

  • Shanda Asset Management Holdings reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 1,533 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $258K.
  • Shanda Asset Management Holdings first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 1 quarter.
  • Shanda Asset Management Holdings's BRAINSTORM CELL THERAPUTC position peaked at $258K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.